| Literature DB >> 32512929 |
Elif Damla Arisan1, Alwyn Dart2, Guy H Grant3, Serdar Arisan4, Songul Cuhadaroglu5, Sigrun Lange6, Pinar Uysal-Onganer7.
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the betacoronavirus family, which causes COVID-19 disease. SARS-CoV-2 pathogenicity in humans leads to increased mortality rates due to alterations of significant pathways, including some resulting in exacerbated inflammatory responses linked to the "cytokine storm" and extensive lung pathology, as well as being linked to a number of comorbidities. Our current study compared five SARS-CoV-2 sequences from different geographical regions to those from SARS, MERS and two cold viruses, OC43 and 229E, to identify the presence of miR-like sequences. We identified seven key miRs, which highlight considerable differences between the SARS-CoV-2 sequences, compared with the other viruses. The level of conservation between the five SARS-CoV-2 sequences was identical but poor compared with the other sequences, with SARS showing the highest degree of conservation. This decrease in similarity could result in reduced levels of transcriptional control, as well as a change in the physiological effect of the virus and associated host-pathogen responses. MERS and the milder symptom viruses showed greater differences and even significant sequence gaps. This divergence away from the SARS-CoV-2 sequences broadly mirrors the phylogenetic relationships obtained from the whole-genome alignments. Therefore, patterns of mutation, occurring during sequence divergence from the longer established human viruses to the more recent ones, may have led to the emergence of sequence motifs that can be related directly to the pathogenicity of SARS-CoV-2. Importantly, we identified 7 key-microRNAs (miRs 8066, 5197, 3611, 3934-3p, 1307-3p, 3691-3p, 1468-5p) with significant links to KEGG pathways linked to viral pathogenicity and host responses. According to Bioproject data (PRJNA615032), SARS-CoV-2 mediated transcriptomic alterations were similar to the target pathways of the selected 7 miRs identified in our study. This mechanism could have considerable significance in determining the symptom spectrum of future potential pandemics. KEGG pathway analysis revealed a number of critical pathways linked to the seven identified miRs that may provide insight into the interplay between the virus and comorbidities. Based on our reported findings, miRNAs may constitute potential and effective therapeutic approaches in COVID-19 and its pathological consequences.Entities:
Keywords: COVID-19; SARS–CoV-2; cell signalling pathways; comorbidities.; coronavirus; microRNAs (miRs 8066, 5197, 3611, 3934-3p, 1307-3p, 3691-3p, 1468-5p); viral pathogenesis
Mesh:
Substances:
Year: 2020 PMID: 32512929 PMCID: PMC7354481 DOI: 10.3390/v12060614
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Similar microRNA (miR) sequences found in SARS-CoV-2-released genomes from different geographical areas.
| miRs | Score | E-Value | Alignment | Wuhan | Italy | UK | Valencia | Turkey | Vero E6 |
|---|---|---|---|---|---|---|---|---|---|
| NC_045512.2 | MT066156.1 | hCoV-19/England/20136087804/2020|EPI_ISL_420910 | MT198652.2 | hCoV-19/Turkey/GLAB-CoV008/2020 | hCoV-19/Turkey/ERAGEM-001/2020 | ||||
| hsa-miR-8066 | 80 | 1.6–2.8 |
| √ | √ | √ | √ | √ | √ |
| hsa-miR-5197-3p | 79 | 1.6–2.8 |
| √ | √ | √ | √ | √ | √ |
| hsa-miR-3611 | 77 | 2.8–3.8 |
| √ | √ | √ | √ | √ | √ |
| hsa-miR-3934-3p | 76 | 3.4–5.0 |
| √ | √ | √ | √ | √ | √ |
| hsa-miR-1468-5p | 71 | 4.7–8.8 |
| √ | √ | √ | √ | √ | √ |
| hsa-miR-1307-3p | 72 | 4.3–6.3 |
| √ | √ | √ | √ | √ | |
| hsa-miR-3691-3p | 74 | 5.0–9.5 |
| √ | √ | √ | √ | √ | |
| hsa-miR-3120-5p | 73 | 6.0–7.2 |
| √ | √ | √ | √ | √ | |
| hsa-miR-3914 | 73 | 6.0–8.5 |
| √ | √ | √ | √ | √ | |
| hsa-miR-3672 | 72 | 7.3–9.8 |
| X | X | X | X | ||
| hsa-miR-7107-3p | 73 | 6.0–6.2 |
| √ | √ | √ | √ | √ | |
| hsa-miR-1287-5p | 73 | 6.0–8.3 |
| √ | √ | √ | √ | √ | |
| hsa-miR-129-2-3p | 73 | 6.0–7.7 |
| √ | √ | √ | |||
| hsa-miR-378c | 71 | 8.8–9.3 |
| √ | √ | √ | |||
| hsa-miR-10397-5p | 72 | 6.9–10.0 |
| √ | √ | √ | |||
| hsa-miR-584-3p | 72 | 7.3–9.8 |
| √ | √ | ||||
| hsa-miR-3085-3p | 71 | 8.8–9.9 |
| √ | √ | √ | |||
| hsa-miR-3191-3p | 70 | 7.4–8.5 |
| √ | √ | ||||
| hsa-miR-148b-3p | 72 | 8.2–9.8 |
| √ | √ | ||||
| hsa-miR-3529-3p | 69 | 9.0 |
| √ | |||||
| hsa-miR-3682-5p | 68 | 9.0 |
| √ | √ |
Figure 1Heat map analysis of KEGG pathway (A) and GO analysis (B) for selected miRs on the microT-CDS database. The heat map is drawn with miRPATH (version 3). Neighbourhood lines indicate the shared target mRNAs found in a defined pathway.
The KEGG (A) and GO (B) enrichment analysis results for miR-8066, 5197-3p, 3611, 3934-3p, 1468-5p, 3691, and 1307-3p.
|
|
|
|
|
| Mucin type O-Glycan biosynthesis | 2.52 × 10−2 | 7 | 3 |
| TGF-beta signaling pathway | 4.96 × 10−1 | 12 | 4 |
| Morphine addiction | 0.0001128919 | 14 | 5 |
| Metabolism of xenobiotics by cytochrome P450 | 0.0002215491 | 5 | 2 |
| Other types of O-glycan biosynthesis | 0.0003646344 | 1 | 1 |
| Vitamin digestion and absorption | 0.001008222 | 2 | 1 |
| Glycosaminoglycan biosynthesis—heparan sulfate/heparin | 0.00385809 | 1 | 1 |
| GABAergic synapse | 0.01342039 | 13 | 4 |
| Cytokine-cytokine receptor interaction | 0.02096334 | 9 | 1 |
| Signaling pathways regulating pluripotency of stem cells | 0.180299 | 9 | 1 |
| Amphetamine addiction | 0.2150865 | 7 | 1 |
| Axon guidance | 0.2239648 | 22 | 3 |
| Hippo signaling pathway | 0.2278356 | 7 | 1 |
| Prolactin signaling pathway | 0.2284669 | 5 | 1 |
| mRNA surveillance pathway | 0.2795597 | 1 | 1 |
| Glycosphingolipid biosynthesis—lacto and neolacto series | 0.3157068 | 1 | 1 |
| Bile secretion | 0.4120997 | 1 | 1 |
| Circadian entrainment | 0.4608082 | 9 | 1 |
| N-Glycan biosynthesis | 0.488078 | 2 | 1 |
| Mismatch repair | 0.6174557 | 1 | 1 |
| Drug metabolism—cytochrome P450 | 0.7063987 | 6 | 1 |
| Glutamatergic synapse | 0.7319762 | 6 | 1 |
| Glycosaminoglycan degradation | 0.7395672 | 2 | 1 |
| Antigen processing and presentation | 0.7591685 | 1 | 1 |
|
|
|
|
|
| organelle | 1 × 10−38 | 848 | 6 |
| cellular nitrogen compound metabolic process | 1 × 10−12 | 414 | 7 |
| ion binding | 8 × 10−8 | 495 | 7 |
| biosynthetic process | 3 × 10−7 | 351 | 7 |
| nucleic acid binding transcription factor activity | 4 × 10−2 | 115 | 6 |
| cellular protein modification process | 2 × 101 | 205 | 7 |
| molecular_function | 5 × 103 | 1303 | 7 |
| cellular_component | 1 × 105 | 1312 | 7 |
| enzyme binding | 2 × 105 | 119 | 5 |
| gene expression | 3 × 105 | 54 | 6 |
| protein binding transcription factor activity | 1 × 106 | 52 | 5 |
| blood coagulation | 0.000176061599974 | 44 | 6 |
| protein complex | 0.00115693944276 | 290 | 5 |
| post-translational protein modification | 0.00185490003064 | 19 | 5 |
| neurotrophin TRK receptor signaling pathway | 0.00197464302174 | 24 | 5 |
| synaptic transmission | 0.00204631087649 | 42 | 5 |
| cellular protein metabolic process | 0.00275618650845 | 39 | 5 |
| small molecule metabolic process | 0.00275618650845 | 170 | 7 |
| cytoskeletal protein binding | 0.00396272124679 | 68 | 4 |
| cell-cell signaling | 0.00396272124679 | 60 | 5 |
| transcription, DNA-templated | 0.00450420995446 | 208 | 6 |
| symbiosis, encompassing mutualism through parasitism | 0.0140041886634 | 41 | 5 |
| catabolic process | 0.0141620388146 | 142 | 6 |
| Fc-epsilon receptor signaling pathway | 0.0222360628043 | 15 | 6 |
| cellular component assembly | 0.02375306792 | 99 | 5 |
| transcription initiation from RNA polymerase II promoter | 0.0250016205995 | 24 | 5 |
| nucleoplasm | 0.0335128910566 | 92 | 6 |
| platelet activation | 0.0350801245107 | 20 | 5 |
| positive regulation of telomere maintenance via telomerase | 0.0370638891992 | 3 | 3 |
| RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription | 0.0448871926331 | 32 | 5 |
| O-glycan processing | 0.0449415771561 | 8 | 5 |
The mutational comparison of selected miRs found on the Wuhan genome compared to other SARS-CoV-2 strains isolated from different geographical regions. % represents the number of viral genome sequences with a single base change in that miR sequence. n = number of viral genomes analysed.
| miRs | Alignment | Wuhan/China | Italy | Spain | France | England | USA | India |
|---|---|---|---|---|---|---|---|---|
|
| ccaaaagaucacauug | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| auucgaagacccagucccuacuu | 0 | 0 | 0 | 0 | 0 | 0.9% | 0 |
|
| ugagaagcaagaaauucuu | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| ucagguuggacagcugg | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| accgaggccacgcggagu | 3.5% | 2.2% | 8.27% | 1.92% | 2.88% | 2.88% | 38.23% |
|
| gagauguugacacagacuuugu | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| cucaguuugccuguuu | 0 | 0 | 2.25% | 0.96% | 0 | 0 | 8.83% |
|
| uguagaggaggcaaagacag | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| caucucacuugcugguuccu | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| ugagucucauggaaaaca | 0 | 0 | 0.75% | 0.96% | 0 | 0 | 0 |
|
| acugggcauugauuuagaugagugg | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| ccaaaaagagaaagucaaca | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| acucaaaccacugaaacagc | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| uucuucaccugaugcugu | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| gccugguuugccuggcac | 0 | 0 | 0.75% | 0 | 0 | 0 | 0 |
|
| ucuggcuguuauggcc | 0 | 0 | 0 | 0 | 0 | 0.96% | 0 |
|
| cugucuauccaguugcgucacca | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| uggcagacgggcgauuuuguu | 0 | 0 | 0 | 0 | 0 | 0 | 2.94% |
|
| auagcacaaguagauguag | 0 | 0 | 0 | 0 | 0 | 0.96% | 0 |
|
| aaguucuaugaugcacag | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| ugauuuuuguggaaagggcu | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Figure 2Rosalind meta-analysis for Bioproject PRJNA615032 was used for differential gene expression between SARS-CoV-2-infected NHEB and A549 cells with their (mock treated) controls (n = 3). 1.5 fold change was accepted as threshold value. (A) MA plot view of differential expression of upregulated and downregulated genes. (B) Heatmap analysis of each clone for 204 differentially expressed gene targets.
BioProject data analysis for differential gene expression between non-treated and SARS-CoV-2-treated NEHB and A549 cells.
|
|
|
| Photodynamic therapy-induced NF-kB survival signaling | 0 |
| IL-18 signaling pathway | 8.6 × 10−9 |
| miRNAs involvement in the immune response in sepsis | 2.4 × 10−8 |
| Cytokines and Inflammatory Response | 9.9 × 10−7 |
| Lung fibrosis | 2.5 × 10−6 |
|
|
|
| Oncostatin M | 0 |
| Interleukin-1 regulation of extracellular matrix | 0 |
| Interleukin-5 regulation of apoptosis | 0 |
| TNF-alpha effects on cytokine activity, cell motility, and apoptosis | 0 |
| Immune system signaling by interferons, interleukins, prolactin, and growth hormones | 0 |
|
|
|
| IL-17 signaling pathway | 1.3 × 10−9 |
| TNF signaling pathway | 1.6 × 10−9 |
| Legionellosis | 3.5 × 10−9 |
| Rheumatoid arthritis | 5.4 × 10−9 |
| Cytokine-cytokine receptor interaction | 6.6 × 10−9 |
|
|
|
| Plasminogen activating cascade | 0.00156 |
| Toll receptor signaling pathway | 0.00911 |
| CCKR signaling map ST | 0.02550 |
| Apoptosis signaling pathway | 0.10282 |
| Blood coagulation | 0.10433 |
|
|
|
| Interferon alpha/beta signaling | 1.6 × 10−9 |
| Interleukin-10 signaling | 2.5 × 10−9 |
| Interleukin-4 and Interleukin-13 signaling | 2.4 × 10−7 |
| Formation of the cornified envelope | 1.3 × 10−5 |
| Chemokine receptors bind chemokines | 0.00047 |
|
|
|
| CD40L Signalling Pathway | 0.25268 |
| NF-kB Signaling Pathway | 0.25268 |
| Toll-Like Receptor Pathway 2 | 0.25268 |
| Capecitabine Metabolism Pathway | 0.25268 |
| Capecitabine Action Pathway | 0.25268 |
|
|
|
| vitamin D3 biosynthesis | 0.03597 |
| guanosine nucleotides degradation | 0.03597 |
| retinoate biosynthesis II | 0.03597 |
| guanosine nucleotides degradation III | 0.03597 |
| adenosine nucleotides degradation II | 0.03597 |
|
|
|
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | 3.8 × 10−5 |
| IL23-mediated signaling events | 0.00050 |
| CD40/CD40L signaling | 0.02539 |
| Glucocorticoid receptor regulatory network | 0.02603 |
| LPA receptor mediated events | 0.04171 |